What Is GxP AI Governance in Life Sciences?

An ‌AI ‌assistant ‌might help a clinical operations team categorise protocol deviations, suggest follow-up questions, or pull relevant sections of standard operating procedures. This could remove many hours of case intake work. However, if the model used, inputs, and usage were not approved by the right people it could create an inspection exposure. This is the short answer to what is GxP AI governance: the controls that allow AI to be used in a defensible and appropriate way within GxP contexts.

This is not some policy document that gets signed off by quality. For life science IT leaders this is a series of decisions that translate into system architecture, validation evidence, security controls, user experience, and change controls. It is the gatekeeper on whether an AI capability integrated into Salesforce Life Sciences Cloud or a custom clinical operations application can support a GxP process without damaging data integrity.

What Is GxP AI Governance?

GxP AI governance is the decision making framework that establishes where and how AI can be deployed within Good Practice processes and workflows, the controls in place, and the evidence that can be produced for inspection. GxP is the suite of quality expectations applied across Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Good Pharmacovigilance Practice (GVP).

This is not about whether the model is accurate in a test environment. It is about whether the intended use case is controlled and governed throughout the lifecycle. If AI is used to route potential adverse events within a pharmacovigilance intake workflow, the business needs to know whether the model is summarising text for a human to review, categorising events, or making a determination that impacts reporting timelines. These are fundamentally different risk profiles.

Electronic records and signatures created and used within regulated processes need appropriate controls over access, audit trails, retention, and validation under 21 CFR Part 11 and EU GMP Annex 11. AI is not exempt from these controls because it is probabilistic. In many cases it raises the bar. A static rules engine is easy to test exhaustively. A large language model can output different text in response to similar prompts and alter behaviour in response to changes in the underlying model, retrieval source, or prompt template.

Governance turns this unknown into a managed design problem. It identifies the intended use, the process owner accountable for the process, the potential impact on patient safety and product quality, the required human review, and the evidence required for release.

The Control Boundary Depends on the Workflow

The rigor of validation needed for AI usage within a GxP context will differ depending on the use case. Applying high risk validation controls to all usage of AI is a drain on quality resources. Applying low risk usage of generative AI features as a productivity enabler creates exposure where it counts most.

Let’s look at three use cases within a clinical operations setting. An internal assistant that summarises a public regulatory guidance document has limited GxP implications, though it will still require data security and acceptable use controls. An assistant that retrieves approved standard operating procedure content to assist a study coordinator drafting a deviation narrative will require more controls over document versioning, retrieval accuracy, and review. A model that recommends whether a deviation meets a reporting threshold has quality implications and should not be permitted to make a determination without human review.

The practical test is whether the output creates, modifies, interprets, or drives a GxP record or decision. The detectability of the process matters too. If a reviewer can easily detect and correct incorrect drafts before approving content, a human in the loop design may be sufficient. If incorrect classification leads to delayed expedited safety reporting, there may be poor downstream detection and the control design will need to be much more stringent.

This is where the risk assessment comes in. GAMP 5’s risk based approach still has value: apply quality resources to functions with potential impact on patient safety, product quality, and data integrity. For AI add these model specific questions: What are the known failure modes? Can output be sufficiently reproduced to investigate? What happens when the source knowledge base changes? Is the system processing protected health information or confidential trial data?

Evidence Must Accompany the AI Lifecycle

GxP AI governance is more than knowing which models are approved for use. Evidence must be captured throughout the AI capability’s lifecycle.

At design time, capture the intended use and prohibited use. “Assist with case intake” is not sufficiently specific. “Extract suspected product, event term, and reporter country from unstructured intake text for reviewer confirmation” is testable. Define the input data, output format, acceptance criteria, escalation path, and person or role permitted to make the final determination.

At go-live, capture requirements, configuration, test scripts, test results, and approval evidence. If the solution follows a retrieval augmented generation pattern, validate the retrieval component separately from the model response. An well constructed answer with root in an obsolete SOP is still a controlled process failure. The document repository will need appropriate effective date controls, approved versions, access restrictions, and the ability to show what source material was available at the time of the interaction.

For a Salesforce deployment this may mean capturing the AI interaction reference, source document version, reviewer disposition, and final approved record in the relevant Salesforce object. The deviation record will contain the submitted text, AI suggestion, reviewer edits, and approval history. Salesforce Shield Event Monitoring and Field Audit Trail can help with aspects of the auditability requirement, but do not replace a validated workflow design or a quality approved records retention policy.

Throughout release, governance becomes operational. Override and accuracy monitoring, exception rates, user override patterns, anomalous access, and change events need to be tracked. A useful metric is not model accuracy. For deviation intake workflow, what percentage of AI suggestions are accepted with little to no material edit required, what percentage is pushed to manual review, what is the cycle time between intake and quality assessment. An increase in overrides could signal source document drift, poor performing prompt, or workflow change that requires revalidation.

Change Control Is Where Many AI Programs Explode

Validated applications change on a release cadence. AI systems can change on a new prompt, revised knowledge article, different embedding model, new version of the vendor model, or altered integration. All can impact the regulated output.

GxP AI governance should define what changes require impact analysis, regression testing, quality approval, and user retraining. The answer will depend on intended use. Updating non-GxP content within a help assistant may only require limited testing. Updating the controlled SOP corpus used to advise batch record exception investigations requires documented review and targeted challenge testing before new content is made available to users.

Vendor management comes into play too. A security documentation from a model provider is useful, but not your validation package. You are still accountable for your intended use, data flows, configuration, and controlled process. Contracts and technical controls should consider data retention, training data usage, geographic processing, incident notification, model version notice, and the ability to disable or roll back a capability.

For businesses dealing with EU data, the regulations of GDPR governing the processing of personal data apply irrespective of whether the use case constitutes GxP. The EU AI Act may also come into play depending on the classification and deployment context of the system. These regimes overlap but are not mutually exclusive: controls over privacy do not prove GxP validation, and a validation package does not establish a lawful basis for processing personal data.

Human Review Must Be Designed, Not Assumed

“Human in the loop” is frequently used as shorthand for safety. It is only a meaningful control when the human reviewer has the authority, context, time, and user experience to meaningfully challenge the output.

A quality reviewer with an AI generated deviation classification and an Approve button only is not exercising meaningful oversight. A better user experience provides source evidence, relevant SOP version, confidence or exception indicators where material, and explicit buttons to approve, edit, reject, or escalate. The user experience should facilitate viewing the human decision in the audit trail rather than hiding it in free text.

This is a UX/UI requirement with practical implications for the user, not a cosmetic concern. If the reviewer cannot see the reasoning behind a recommendation or quickly correct it, they either overtrust the system or bypass it. Both undermine adoption and control. In engagements like this, the aim is typically to reduce the volume of review work while maintaining the rights of the accountable expert to make a decision.

Building a Governance Model That Can Operate

The ‌best ‌is ‌not committee based. Quality owns the GxP meaning. The process owner owns the outcome and the residual risk. IT owns the platform controls, integrations, identity model and the release process. Data and AI owns evaluation, monitoring and technical documentation. Security and privacy owns the data boundary.

Focus on a few high value bounded workflows rather than a broad brush approach to an internal chatbot. An pharmacovigilance intake assistant with mandatory reviewer sign-off, a controlled source corpus, and defined acceptance testing is easier to govern than an unrestricted assistant with access to all document repositories. Where Salesforce Life Sciences Cloud fits, configure the data model and approvals. Where you need custom evidence capture, evaluation services or controlled orchestration that the platform cannot provide cleanly, custom code is probably the better decision.

The test is if a regulator, regulator or quality asks you why an AI output influenced your GxP record, you can point them to the intent of use, the controls in place, the evidence, the human decision and the change history. Before you ever release the first production prompt.